Is continuation of anti-tumor necrosis factor-α therapy a safe option for patients who have developed pulmonary mycobacterial infection? : Case presentation and literature review

Clinical Rheumatology

Volumn 31, Issue 2, 2012, Pages 203-210

  Mori, Shunsuke ^a   Sugimoto, Mineharu ^a  

^a Kumamoto Saishunsou National Hospital   (Japan)

Author keywords

Anti mycobacterial therapy; Nontuberculous mycobacteria; Pulmonary infection; Rheumatoid arthritis; Tumor necrosis factor

Indexed keywords

CLARITHROMYCIN; ETANERCEPT; ETHAMBUTOL; ISONIAZID; METHOTREXATE; RIFAMPICIN; TACROLIMUS;

AGED; ATYPICAL MYCOBACTERIOSIS; BRONCHIECTASIS; CASE REPORT; COMPUTER ASSISTED TOMOGRAPHY; COUGHING; DRUG DOSE REDUCTION; DRUG WITHDRAWAL; FEMALE; HUMAN; INFORMED CONSENT; LOW DRUG DOSE; LUNG INFECTION; LUNG TUBERCULOSIS; MYCOBACTERIUM INTRACELLULARE; PRIORITY JOURNAL; REVIEW; RHEUMATOID ARTHRITIS; THORAX RADIOGRAPHY;

AGED; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HUMANS; IMMUNOGLOBULIN G; MYCOBACTERIUM INFECTIONS, NONTUBERCULOUS; RECEPTORS, TUMOR NECROSIS FACTOR;

EID: 84856751835     PISSN: 07703198     EISSN: 14349949     Source Type: Journal    
DOI: 10.1007/s10067-011-1902-3     Document Type: Review

References (49)

1. RS Wallis MS Broder JY Wong ME Hanson DO Beenhouwer 2004 Granulomatous infectious diseases associated with tumor necrosis factor antagonists Clin Infect Dis 38 1261 1265 15127338 10.1086/383317 1:STN:280:DC%2BD2c3islCksg%3D%3D (Pubitemid 38608568)
2. KL Winthrop S Yamashita SE Beekmann PM Polgreen 2008 Mycobacterial and other serious infections in patients receiving anti-tumor necrosis factor and other newly approved biologic therapies: case finding through the emerging infections network Clin Infect Dis 46 1738 1740 18419421 10.1086/587989 (Pubitemid 351706773)
3. R Koike T Takeuchi K Eguchi N Miyasaka 2007 Update on the Japanese guidelines for the use of infliximab and etanercept in rheumatoid arthritis Mod Rheumatol 17 451 458 18084695 10.1007/s10165-007-0626-3 1:CAS:528: DC%2BD1cXisFCjtbo%3D
4. I Solovic M Sester JJ Gomez-Reino HL Rieder S Ehlers HJ Milburn, et al. 2010 The risk of tuberculosis related to tumour necrosis factor antagonist therapies: a TBNET consensus statement Eur Respir J 36 1185 1206 20530046 10.1183/09031936.00028510 1:CAS:528:DC%2BC3MXhtVWqtA%3D%3D
5. J van Ingen MJ Boeree PN Dekhuijzen D van Soolingen 2008 Mycobacterial disease in patients with rheumatic disease Nat Clin Pract Rheumatol 4 649 656 19037226 10.1038/ncprheum0949
6. DE Griffith T Aksamit BA Brown-Elliott A Catanzaro C Daley F Gordin, et al. 2007 An official ATS/IDSA statement: diagnosis, treatment, and prevention of nontuberculous mycobacterial diseases Am J Respir Crit Care Med 175 367 416 17277290 10.1164/rccm.200604-571ST 1:CAS:528:DC%2BD2sXjtlajsL4%3D
7. KG Saag GG Teng NM Patkar J Anuntiyo C Finney JR Curtis, et al. 2008 American College of Rheumatology 2008 recommendations for the use of nonbiologic and biologic disease-modifying antirheumatic drugs in rheumatoid arthritis Arthritis Rheum 59 762 784 18512708 10.1002/art.23721 1:CAS:528: DC%2BD1cXot1Wgs74%3D (Pubitemid 351847559)
8. I Marie P Heliot F Roussel F Herve JF Muir H Levesque 2005 Fatal Mycobacterium peregrinum pneumonia in refractory polymyositis treated with infliximab Rheumatology (Oxford) 44 1201 1202 10.1093/rheumatology/keh700 1:STN:280:DC%2BD2MvkslWgtg%3D%3D (Pubitemid 41236037)
9. N Maimon J Brunton AK Chan TK Marras 2007 Fatal pulmonary Mycobacterium xenopi in a patient with rheumatoid arthritis receiving etanercept Thorax 62 739 740 17687101 10.1136/thx.2005.056952
10. JE Thomas CR Taoka BT Gibbs SL Fraser 2006 Fatal pulmonary Mycobacterium abscessus infection in a patient using etanercept Hawaii Med J 65 12 15 16602610
11. E Besada 2011 Rapid growing mycobacteria and TNFalpha blockers: case report of a fatal lung infection with Mycobacterium abscessus in a patient treated with infliximab, and literature review Clin Exp Rheumatol 29 705 707 21906433 1:STN:280:DC%2BC3MfislGluw%3D%3D
12. EM Salvana GS Cooper RA Salata 2007 Mycobacterium other than tuberculosis (MOTT) infection: an emerging disease in infliximab-treated patients J Infect 55 484 487 17920687 10.1016/j.jinf.2007.08.007 (Pubitemid 350082471)
13. RM Swart J van Ingen D van Soolingen R Slingerland WD Hendriks JG den Hollander 2009 Nontuberculous mycobacteria infection and tumor necrosis factor-alpha antagonists Emerg Infect Dis 15 1700 1701 19861085 1:CAS:528:DC%2BD1MXhtlCnsL%2FN
14. T Esaki M Sugimoto S Mori A Yamashita M Matsumoto H Kohrogi 2010 A case of pulmonary nontuberculous mycobacteriosis aggravated during treatment with etanercept for rheumatoid arthritis Nihon Kokyuki Gakkai Zasshi 48 312 316 20432974
15. H Okubo M Iwamoto T Yoshio H Okazaki T Kato M Bandoh, et al. 2005 Rapidly aggravated Mycobacterium avium infection in a patient with rheumatoid arthritis treated with infliximab Mod Rheumatol 15 62 64 17028825 10.1007/s10165-004- 0360-z (Pubitemid 40298426)
16. A Martin-Aspas F Guerrero-Sanchez P Garcia-Martos E Gonzalez-Moya F Medina-Varo JA Giron Gonzalez 2008 Bilateral pneumonia by Mycobacterium aurum in a patient receiving infliximab therapy J Infect 57 167 169 18555532 10.1016/j.jinf.2008.04.010
17. J van Ingen M Boeree M Janssen E Ullmann W de Lange P de Haas, et al. 2007 Pulmonary Mycobacterium szulgai infection and treatment in a patient receiving anti-tumor necrosis factor therapy Nat Clin Pract Rheumatol 3 414 419 17599076 10.1038/ncprheum0538 (Pubitemid 47034543)
18. E Rallis E Koumantaki-Mathioudaki E Frangoulis E Chatziolou A Katsambas 2007 Severe sporotrichoid fish tank granuloma following infliximab therapy Am J Clin Dermatol 8 385 388 18039022 10.2165/00128071-200708060-00009 (Pubitemid 350174541)
19. K Yim SH Nazeer D Kiska FB Rose D Brown MH Cynamon 2004 Recurrent Mycobacterium xenopi infection in a patient with rheumatoid arthritis receiving etanercept Scand J Infect Dis 36 150 154 15061673 10.1080/00365540310017474 (Pubitemid 38313045)
20. N Chopra AE Kirschenbaum D Widman 2002 Mycobacterium marinum tenosynovitis in a patient on etanercept therapy for rheumatoid arthritis J Clin Rheumatol 8 265 268 17041383 10.1097/00124743-200210000-00007
21. JA Dare S Jahan K Hiatt KD Torralba 2009 Reintroduction of etanercept during treatment of cutaneous Mycobacterium marinum infection in a patient with ankylosing spondylitis Arthritis Rheum 61 583 586 19405014 10.1002/art.24095 1:CAS:528:DC%2BD1MXptFCkt78%3D
22. MW Stewart S Alvarez WW Ginsburg R Shetty WC McLain JP Sleater 2006 Visual recovery following Mycobacterium chelonae endophthalmitis Ocul Immunol Inflamm 14 181 183 16766402 10.1080/09273940600678062 (Pubitemid 43890775)
23. MB Chang JC Sri M Driscoll AA Gaspari 2011 Mycobacterium fortuitum infection following adalimumab treatment for psoriasis and subsequent complication-free treatment with alternate TNF-a blockers J Drugs Dermatol 10 914 916 21818515
24. N Kluger P Cohen C Fallet-Bianco L Guillevin 2010 Mycobacterium chelonae infection under adalimumab therapy for spondylarthritis Clin Exp Rheumatol 28 101 102 20346249 1:STN:280:DC%2BC3c3hslWmtg%3D%3D
25. JC Fallon S Patchett C Gulmann GM Murphy 2008 Mycobacterium marinum infection complicating Crohn's disease, treated with infliximab Clin Exp Dermatol 33 43 45 17983451 1:STN:280:DC%2BD1c%2FgvFGhtQ%3D%3D (Pubitemid 350308531)
26. N Boulman M Rozenbaum G Slobodin I Rosner 2006 Mycobacterium fortuitum infection complicating infliximab therapy in rheumatoid arthritis Clin Exp Rheumatol 24 723 17207395 1:STN:280:DC%2BD2s%2FhtVGjtw%3D%3D (Pubitemid 46138811)
27. JR Danko WR Gilliland RS Miller CF Decker 2009 Disseminated Mycobacterium marinum infection in a patient with rheumatoid arthritis receiving infliximab therapy Scand J Infect Dis 41 252 255 19266397 10.1080/00365540902774599
28. JM Ramos MF Garcia-Sepulcre JC Rodriguez S Padilla F Gutierrez 2010 Mycobacterium marinum infection complicated by anti-tumour necrosis factor therapy J Med Microbiol 59 617 621 20133411 10.1099/jmm.0.017277-0
29. AA Elyousfi JR Leiter MJ Goytan DB Robinson 2009 Mycobacterium heckeshornense lumbar spondylodiskitis in a patient with rheumatoid arthritis receiving etanercept treatment J Rheumatol 36 2130 2131 19738230 10.3899/jrheum.090056
30. AH Mufti BW Toye RR McKendry JB Angel 2005 Mycobacterium abscessus infection after use of tumor necrosis factor alpha inhibitor therapy: case report and review of infectious complications associated with tumor necrosis factor alpha inhibitor use Diagn Microbiol Infect Dis 53 233 238 16249064 10.1016/j.diagmicrobio.2005.06.006 1:CAS:528:DC%2BD2MXht1SksLrF (Pubitemid 41607629)
31. J Malkin A Shrimpton M Wiselka MR Barer M Duddridge N Perera 2009 Olecranon bursitis secondary to Mycobacterium kansasii infection in a patient receiving infliximab for Behcet's disease J Med Microbiol 58 371 373 19208889 10.1099/jmm.0.006809-0
32. JM Shehan DP Sarma 2008 Mycobacterium mucogenicum: report of a skin infection associated with etanercept Dermatol Online J 14 5 18319022
33. F Diaz JC Urkijo F Mendoza JM de la Viuda M Blanco A Unzurrunzaga, et al. 2008 Mycobacterium chelonae infection associated with adalimumab therapy Scand J Rheumatol 37 159 160 18415777 10.1080/03009740701716876 1:STN:280: DC%2BD1c3lsVGmtQ%3D%3D (Pubitemid 351536080)
34. AS Bauer PE Blazar BE Earp BP Simmons 2010 Mycobacterial hand infections occurring postoperatively in patients treated with tumor necrosis factor-alpha inhibitors for inflammatory arthritis: report of three cases J Hand Surg Am 35 104 108 20117311 10.1016/j.jhsa.2009.09.018
35. C Garzoni S Adler C Boller H Furrer PM Villiger 2010 Possible role of anti-TNF monoclonal antibodies in the treatment of Mycobacterium marinum infection Rheumatology (Oxford) 49 1991 1993 10.1093/rheumatology/keq146 1:CAS:528:DC%2BC3cXhtFGhtLfK
36. S Steyaert G Stappaerts P Mareen J Dierick 2011 Soft tissue infections with atypical mycobacteria in two patients with inflammatory rheumatic diseases using TNF-inhibitors and/or leflunomide Acta Clin Belg 66 144 147 21630616 1:STN:280:DC%2BC3MrmslOltg%3D%3D
37. I Yeh G Evan CH Jokinen 2011 Cutaneous mycobacterial spindle cell pseudotumor: a potential mimic of soft tissue neoplasms Am J Dermatopathol 33 e66 e69 21712686 10.1097/DAD.0b013e3182120ae3
38. BG Levesque WJ Sandborn 2011 Mycobacterium marinum infection in the setting of antitumor necrosis factor alpha therapy for Crohn's disease Inflamm Bowel Dis 17 1443 1444 21560204 10.1002/ibd.21512
39. RS Wallis 2005 Reconsidering adjuvant immunotherapy for tuberculosis Clin Infect Dis 41 201 208 15983916 10.1086/430914 1:CAS:528:DC%2BD2MXmvVylt7g%3D (Pubitemid 40962501)
40. SM Arend EM Leyten WP Franken EM Huisman JT van Dissel 2007 A patient with de novo tuberculosis during anti-tumor necrosis factor-alpha therapy illustrating diagnostic pitfalls and paradoxical response to treatment Clin Infect Dis 45 1470 1475 17990230 10.1086/522993 1:CAS:528:DC%2BD2sXhsVOqsb3L (Pubitemid 351411877)
41. C Garcia Vidal S Rodriguez Fernandez J Martinez Lacasa M Salavert R Vidal M Rodriguez Carballeira, et al. 2005 Paradoxical response to antituberculous therapy in infliximab-treated patients with disseminated tuberculosis Clin Infect Dis 40 756 759 15714425 10.1086/427941 (Pubitemid 40381354)
42. RS Wallis C van Vuuren S Potgieter 2009 Adalimumab treatment of life-threatening tuberculosis Clin Infect Dis 48 1429 1432 19364287 10.1086/598504
43. TK Blackmore L Manning WJ Taylor RS Wallis 2008 Therapeutic use of infliximab in tuberculosis to control severe paradoxical reaction of the brain and lymph nodes Clin Infect Dis 47 e83 e85 18840076 10.1086/592695 1:CAS:528:DC%2BD1cXhsVeqs7jE
44. S Aslanidis A Pyrpasopoulou S Douma K Petidis 2008 Is it safe to readminister tumor necrosis factor alpha antagonists following tuberculosis flare? Arthritis Rheum 58 327 328 18163500 10.1002/art.23210
45. T Matsumoto T Tanaka I Kawase 2006 Infliximab for rheumatoid arthritis in a patient with tuberculosis N Engl J Med 355 740 741 16914717 10.1056/NEJMc053468 1:CAS:528:DC%2BD28Xot12rtbg%3D
46. B Denis A Lefort RM Flipo F Tubach M Lemann P Ravaud, et al. 2008 Long-term follow-up of patients with tuberculosis as a complication of tumour necrosis factor (TNF)-alpha antagonist therapy: safe re-initiation of TNF-alpha blockers after appropriate anti-tuberculous treatment Clin Microbiol Infect 14 183 186 18076664 10.1111/j.1469-0691.2007.01891.x 1:CAS:528:DC%2BD1cXis1agt7w%3D
47. KL Winthrop E Chang S Yamashita MF Iademarco PA LoBue 2009 Nontuberculous mycobacteria infections and anti-tumor necrosis factor-alpha therapy Emerg Infect Dis 15 1556 1561 19861045 1:CAS:528:DC%2BD1MXhtlCns7bF
48. J Glassroth 2008 Pulmonary disease due to nontuberculous mycobacteria Chest 133 243 251 18187749 10.1378/chest.07-0358
49. S Yamori M Tsukamura 1992 Comparison of prognosis of pulmonary diseases caused by Mycobacterium avium and by Mycobacterium intracellulare Chest 102 89 90 1623801 10.1378/chest.102.1.89 1:STN:280:DyaK38zisVSjtg%3D%3D